EZH2 and epithelioid sarcoma: Tazemetostat (EPZ‐6438) is a clinically advanced EZH2 inhibitor that has therapeutic efficacy against B‐cell non‐Hodgkin lymphoma and epithelioid sarcoma in several early Phase (I–II) clinical trials.100, 101, 102